Skip to main content
GenMont logo

GenMont — Investor Relations & Filings

Ticker · 3164 ISIN · TW0003164000 TW Manufacturing
Open in API
Filings indexed 1,625 across all filing types
Latest filing 2014-01-03 Regulatory Filings
Country TW Taiwan
Listing TW 3164

About GenMont

www.genmont.com.tw

GenMont Biotech Inc. specializes in the research, development, and manufacturing of functional probiotics and postbiotics. The company operates advanced fermentation and production platforms for concentrated fermented milk, lactic acid bacteria powders, and functional microorganism strains. Its product portfolio features patented probiotic solutions targeting diverse health areas, including immune modulation, metabolic health, dental hygiene, digestive function, weight management, and pet wellness. Key proprietary strains include L. paracasei 33 and GMNL-32. GenMont leverages its technology platforms and extensive patent portfolio to deliver scientifically-backed health supplements. Beyond its proprietary brands, the company provides original equipment manufacturing (OEM) services, supporting the global market with high-quality probiotic and postbiotic ingredients certified by international standards.

Recent filings

Filing Released Lang Actions
公告本公司申請股票上櫃轉上市時所出具之承諾事項 暨其後續執行情形
Regulatory Filings Classification · 95% confidence The document is a public announcement from a listed company (景岳生物科技股份有限公司) regarding the commitments made when applying for stock listing transfer from OTC to main board and the subsequent execution status for the fourth quarter of 2013 (102年度第4季). It references compliance with Taiwan Stock Exchange regulations and details specific commitments and follow-up actions. The document length is short (1004 characters) and it is an announcement of compliance and status rather than a full financial report or detailed filing. It does not contain financial statements or detailed financial data. Therefore, it is best classified as a Regulatory Filing (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2014-01-03 Chinese
公告本公司一０二年第一次股東臨時會重要決議事項
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a public announcement from a company (3164 景岳) regarding the important resolutions passed at an Extraordinary General Meeting (EGM) held on 102/12/31 (Taiwan calendar year). The resolutions include approval of the restated 101 fiscal year financial report and amendments to the company's articles and asset acquisition/disposal procedures. The document is brief (548 characters) and serves as an announcement of meeting outcomes rather than the full report itself. It does not contain detailed financial statements or substantive financial data. Therefore, it fits best under the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2013-12-31 Chinese
澄清新聞媒體報導
Regulatory Filings Classification · 95% confidence The document is a short announcement from a company (景岳生物科技股份有限公司) clarifying a media report about a potential acquisition (merger) involving the company. It states the date of the event and clarifies that official information should be based on public disclosures. The document is only 635 characters long and does not contain any detailed financial data, financial statements, or comprehensive report content. It is essentially a clarification or regulatory announcement about a merger-related news item, but it does not contain merger documents or filings themselves. Given the short length and nature of the content, it fits best as a Regulatory Filing (RNS) rather than a full M&A filing or report. Therefore, the classification is Regulatory Filings (RNS) with high confidence.
2013-12-30 Chinese
102年年報及股東會資料 — 2013_3164_20131231F05.pdf
Annual Report Classification · 95% confidence The document is a detailed record of an extraordinary shareholders meeting (股東臨時會議事錄) held by 景岳生物科技股份有限公司, including the approval of the restated 101年度 (2012) financial statements and consolidated financial statements. It contains extensive financial data such as balance sheets, income statements, cash flow statements, and notes, as well as auditor's reports from 資誠聯合會計師事務所. The document includes management discussion and approval of financial reports, detailed financial tables, and auditor opinions, indicating it is a comprehensive financial report for a fiscal year. The presence of restated financials and auditor's reports aligns with an Annual Report (10-K) type filing. It is not a brief announcement or a certification letter, but a full financial report with substantive financial data and analysis. Therefore, the document is best classified as an Annual Report (10-K). FY 2012
2013-12-13 Chinese
102年年報及股東會資料 — 2013_3164_20131231F14.pdf
Regulatory Filings Classification · 95% confidence The document is a detailed procedural guideline titled "取得或處分資產處理程序" (Procedures for Acquisition or Disposal of Assets) for a company, referencing specific laws such as the Securities Exchange Act and regulations from the Financial Supervisory Commission. It outlines internal control procedures, evaluation methods, authorization limits, risk management, and disclosure requirements related to asset transactions including securities, real estate, intangible assets, and derivatives. It also covers related-party transactions, merger and acquisition procedures, and compliance with regulatory disclosure obligations. The document is a policy or procedural manual rather than a financial report, earnings release, or announcement. It does not contain financial statements, audit opinions, or voting results. It is not a presentation or transcript. It is a regulatory compliance document detailing internal processes and legal adherence for asset transactions. Such documents do not fit into categories like Annual Report, Interim Report, Earnings Release, or M&A filings. The closest fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory or compliance documents that do not fit other categories.
2013-12-13 Chinese
102年年報及股東會資料 — 2013_3164_20131231F02.pdf
AGM Information Classification · 95% confidence The document is a detailed agenda and handbook for an Extraordinary General Meeting (EGM) of GenMont Biotech Inc. held on December 31, 2013 (Republic of China year 102). It includes the meeting procedures, agenda items such as approval of restated financial statements for the fiscal year 2012 (ROC 101), amendments to company bylaws, and asset acquisition/disposal procedures. The document contains extensive financial statements, audit reports by an accounting firm, and supervisory review reports. The presence of detailed financial statements and audit reports within the meeting materials indicates this is the actual meeting handbook and materials shared during the shareholders' meeting, not just an announcement or summary. This fits the definition of AGM Information (AGM-R), which includes presentations and materials shared during general meetings (including extraordinary meetings). Although it is an extraordinary meeting, the category AGM-R covers such shareholder meeting materials. Therefore, the document is best classified as AGM Information (AGM-R).
2013-12-13 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.